Followers | 1 |
Posts | 1 |
Boards Moderated | 0 |
Alias Born | 12/15/2014 |
Monday, December 15, 2014 1:39:23 PM
I am new to this board. I have been an investor of ONCS for over a year.
Seeing that there has been a lot of confusion as to the value of Immunopulse, I would like to provide a valuation case. It goes a bit into the science and the positioning of Immunopulse within the fast-moving immunotherapy space.
http://tinyurl.com/o4zztqf
Fundamentally, ONCS closest comparison is Tvec (acquired for $1B by Amgen in 2011). Both are being evaluated as combination therapies with Merck's PD1. Both have a very similar mechanism of action. The upcoming Immunopulse+PD1 trial has been significantly de-risked by Tvec's combination Yervoy trial results (mid-2014).
Best,
Justice
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM